What is orforglipron?
Orforglipron is an oral experimental, once-daily weight loss/ type 2 diabetes medication that is easier to administer and may be less expensive than current injectable anti-obesity/type 2 GLP-1 drugs already on the market such as Ozempic or Trulicity, which are given by injection.
Lilly plans to submit the pill for FDA approval as a weight-loss treatment by the end of 2025 and for diabetes treatment in 2026.
How is orforglipron administered?
Orforglipron is administered orally, once daily as a pill.
How does orforglipron work?
Orforglipron is a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist that works by binding to GLP-1 receptors and stimulating insulin release from the pancreas when it is needed. It also slows down how fast food travels through your digestive tract. This can help you feel fuller for longer, reduce how much you eat, and lead to weight loss.
Orforglipron differs from other GLP-1 drugs because of its small molecule structure, unlike the large molecules found in typical GLP-1 medications. This small size may help the body absorb it more easily.
What are the side effects of orforglipron?
The most common side effects were mild to moderate gastrointestinal events such as diarrhea, nausea, constipation, abdominal pain, or vomiting.
The side effect profile is similar to semaglutide but different with diarrhea leading the list. Vomiting is not as frequently reported as with semaglutide.
How effective is orforglipron?
In the ACHIEVE-1 phase 3 trial, 559 type 2 diabetes patients received orforglipron (3, 12, or 36 mg) or placebo for 40 weeks. The drug significantly reduced A1c levels (1.3-1.6 percentage points) compared to placebo (0.1). More than 65% of those taking the 36-mg dose achieved an A1c level of 6.5% or below.
Weight loss ranged from 4.7-7.9% with orforglipron versus 1.6% with placebo, with Lilly noting patients hadn't reached maximum weight reduction when the study ended.
Related questions
- Is obesity a major risk factor for Covid-19?
- What is the natural Mounjaro recipe for weight loss?
- Mounjaro vs Ozempic: Which is right for you?
Previous studies
One phase 2 randomized, double-blind trial of 272 participants with an average baseline weight of 108.7kg (average BMI of 37.9 kg/m2) reported (Warton, et al. 2023):
- A weight change of at least 10% occurred in 46% to 75% of people who received orforglipron by week 36 compared to only 9% of those receiving placebo (an inactive tablet)
- The average change from the starting weight was a loss of 9.4% to 14.7% with orforglipron compared to a loss of 2.3% with placebo
- All prespecified improvements in weight and cardiometabolic measures were met by the trial
- The most common side effects were mild to moderate gastrointestinal events and led to discontinuation of orforglipron in 10% to 17% of participants.
A second phase 2 randomized, double-blind trial of 383 participants with an average BMI of 35.2 kg/m2 reported (Frias, et al. 2023):
- Dosages of orforglipron 12mg and greater showed significant reductions in HbA1c and bodyweight compared with placebo or dulaglutide
- At week 26, there was a reduction in HbA1c of up to 2.1% with orforglipron, 0.43% with placebo, and 1.10% with dulaglutide.
- A reduction in body weight after 26 weeks of 10.1kg with orforglipron versus a loss of 2.2kg for placebo and a loss of 3.9kg for dulaglutide was also reported.
- Adverse events were reported in 61.8% to 88.9% of orforglipron treated patients, compared to 61.8% with placebo and 56% with dulaglutide. Most adverse events were mild to moderate gastrointestinal events. Clinically significant hypoglycemia was reported in 3 orforglipron patients and 1 dulaglutide patient. 80 patients did not complete 26 weeks of treatment.
Who makes orforglipron?
Orforglipron is made by Lilly.
Lilly also makes Mounjaro, an injectable dual GIP/GLP-1 receptor agonist which helps lower blood sugar levels in people with type 2 diabetes.
References
- Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet. June 23, 2023. https://doi.org/10.1016/S0140-6736(23)01302-8
- Wharton S, Blevins, T, Connery L et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England Journal of Medicine. June 23, 2023. DOI: 10.1056/NEJMoa2302392
- Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial. April 17, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
Read next
Zepbound vs. Mounjaro: Comparison Guide for Weight Loss and Diabetes Treatment
Zepbound and Mounjaro contain the same active ingredient (tirzepatide) and both are made by Eli Lilly and Company, but they have different FDA approved uses and insurance coverage. Zepbound is approved for chronic weight management and obstructive sleep apnea (OSA) and Mounjaro is approved for type 2 diabetes.
Continue reading
Ozempic Side Effects to Watch For
The most common Ozempic side effects with Ozempic include stomach problems, like nausea, vomiting, diarrhea, stomach pain and constipation. These tend to be mild-to-moderate and usually clear up in a few weeks in most people. Low blood sugar (hypoglycemia) is also a common side effect (when used with certain other diabetes treatments) and it can be serious. Continue reading
Why am I not losing weight on Mounjaro?
It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro. Other reasons include the need to follow a reduced calorie diet and exercise program, your dose may need to be increased, or side effects may affect your treatment. Continue reading
See also:
Related medical questions
- Ozempic Mounjaro Wegovy & Zepbound: Weight Loss Compared
- Wegovy vs Ozempic: Which is Right for You?
- How long does it take for Ozempic to work?
- How long to see weight loss results with Wegovy?
- Does levothyroxine cause weight gain or loss?
- Tirzepatide vs semaglutide: How do they compare?
- Do Ozempic, Wegovy, Mounjaro & Zepbound cause hair loss?
- How does Ozempic work for weight loss?
- Does Wellbutrin XL/SR cause weight gain or loss?
- Why does Lexapro cause weight gain? Complete Patient Guide
- What happens when you stop taking Ozempic?
- Does Lyrica (pregabalin) cause weight gain?
- Does Ozempic need to be refrigerated?
- How much is Zepbound with or without insurance?
- Which GLP-1 drug is best for weight loss?
- Does gabapentin cause weight gain?
- Does Zoloft (sertraline) cause weight gain?
- Will my insurance cover the cost of Ozempic?
- Saxenda vs Ozempic: For Weight Loss?
- How does Mounjaro Work for Weight Loss?
- How long does it take for Zepbound to work?
- Does Prozac cause weight gain or loss?
- Can you get tirzepatide from a compounding pharmacy?
- Does topiramate cause weight loss?
Related support groups
- Weight Loss (Obesity/Overweight) (863 questions, 1,513 members)
- Diabetes, Type 2 (511 questions, 1,431 members)